Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Tarih
2020
Yazar
Villegas, Augusto
Lee, Ki Hyeong
Cho, Byoung Chul
Planchard, David
Paz-Ares, Luis
Spigel, David R.
Wadsworth, Catherine
Taboada, Maria
Dennis, Phillip A.
ÖZGÜROĞLU, Mustafa
Antonia, Scott J.
Faivre-Finn, Corinne
Vansteenkiste, Johan F.
Gray, Jhanelle E.
Daniel, Davey
Vicente, David
Murakami, Shuji
Hui, Rina
Kurata, Takayasu
Chiappori, Alberto
Üst veri
Tüm öğe kaydını göster
Özet
Introduction: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p < 0.0001) and overall survival (OS) (HR = 0.68, 95% CI: 0.53-0.87, p = 0.00251), with manageable safety and no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study.
Bağlantı
http://hdl.handle.net/20.500.12627/27542
https://doi.org/10.1016/j.jtho.2019.10.002
Koleksiyonlar